Biotechnology FDA Approves Novartis’ Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors – Novartis (NYSE:NVS) Read more
Biotechnology FDA Mandates “Boxed Warning” For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies – Johnson & Johnson (NYSE:JNJ), Novartis (NYSE:NVS), Gilead Sciences (NASDAQ:GILD), Bristol-Myers Squibb (NYSE:BMY) Read more
Biotechnology Novartis Multiple Sclerosis Drug Kesimpta Shows Substantial Benefit Of Up To 6 Years – Novartis (NYSE:NVS) Read more
Biotechnology Novartis Reveals Promising Gene Therapy Data for Treating Spinal Muscular Atrophy in Older Children – Novartis (NYSE:NVS) Read more
Biotechnology Novartis Agrees To Acquire German Blood Cancer-Drug Developer MorphoSys For €2.7B – MorphoSys (NASDAQ:MOR), Novartis (NYSE:NVS) Read more
